Recent Quotes (30 days)

You have no recent quotes
chg | %

Spectral Diagnostics Inc  

(Public, TSE:SDI)   Watch this stock  
Find more results for SDI
-0.010 (-3.03%)
Oct 24 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.32 - 0.32
52 week 0.22 - 0.77
Open 0.32
Vol / Avg. 12,148.00/56,215.00
Mkt cap 57.52M
P/E     -
Div/yield     -
EPS -0.09
Shares 179.74M
Beta 1.34
Inst. own     -
Aug 13, 2014
Q2 2014 Spectral Diagnostics Inc Earnings Release

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -315.04% -423.17%
Operating margin -315.04% -425.37%
EBITD margin - -415.94%
Return on average assets -205.78% -102.68%
Return on average equity -644.02% -138.99%
Employees 20 -
CDP Score - -


135-2 The West Mall
+1-416-6263233 (Phone)
+1-416-6267383 (Fax)

Website links


Spectral Diagnostics Inc. (Spectral) focuses on the development and commercialization, in North America, treatment for severe sepsis and septic shock. The Company also manufactures and sells certain reagents. Its products include Rapid Diagnostics for Sepsis, Endotoxin Activity Assay (EAA) and Toraymyxin. As of December 31, 2011, Spectral�s EAA endotoxin measurement was the only the United Sates Food and Drug Administration (FDA) cleared diagnostic on the market. Spectral Diagnostics (US) Inc. and Spectral Diagnostics (New Brunswick) Inc. are its subsidiaries.

Officers and directors

Anthony P. Bihl III Chairman of the Board
Age: 57
Paul M. Walker M.D., Ph.D. President, Chief Executive Officer, Director
Anthony Businskas Chief Financial Officer, Executive Vice President, Corporate Secretary
Guadagni Guadagni Vice President - Sales and Marketing
Debra M. Foster RN Vice President - Clinical Development
William C. Stevens Director
Guillermo A. Herrera Independent Director